[Home ] [Archive]   [ فارسی ]  
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Home::
Journal Information::
Articles archive::
For Authors::
For Reviewers::
Subscription::
Contact us::
Site Facilities::
Webmail::
::
Search in website

Advanced Search
..
Receive site information
Enter your Email in the following box to receive the site news and information.
..
Journal Citation Index

 

Citation Indices from GS

AllSince 2021
Citations116895622
h-index4326
i10-index315143

 

..
Central Library of Kurdistan University of Medical Sciences
AWT IMAGE
..
Vice-Chancellery for Research and Technology
AWT IMAGE
..
SCImago Journal & Country Rank
:: Search published articles ::
Showing 1 results for Virtual Screening

Fatemeh Abdi, Monireh Movahedi, Mir Mohammad Alavi Nikje, Sako Mirzaie,
Volume 27, Issue 1 (3-2022)
Abstract

Background and Aim: Nowadays, diabetes mellitus is a major challenge for human health. Serine/threonine-protein kinase 4 (STK4) is a main regulator of pancreatic β-cell death and dysfunction, and its over activation can lead to type 1 and type 2 diabetes. Deficiency of STK4 restores functional β-cells and normoglycemia. In the current study, for the first time, we used molecular modeling to discover a potent STK4 inhibitor.
Materials and Methods: In this study, among 51220 molecules in ZINC database, we used the molecular docking method for virtual screening process to select the potent and effective inhibitors against STK4. We used Desmond software for molecular dynamics (MD) simulations studies of the structures with the lowest free binding energy for 100 ns. The ADME properties of the selected compounds were calculated by Qikprop software.
Results: Virtual screening results showed that compounds with ZINC ID of ZINC95918625, ZINC85569233, ZINC03874317, ZINC00105086 and ZINC14819359 can be considered as STK4 inhibitors. Among these compounds, ZINC95918625 had the lowest free binding energy (-11.67 kcal/mol). After the 100 ns MD studies, ZINC95918625 interacted with STK4 residues of Lys59, Glu73, Cys105, and Gly153 via hydrogen bonding. ADME analysis exhibited that all pharmaco-kinteic parameters of ZINC95918625 were within the reasonable range.
Conclusion: Our study can provide valuable information about new inhibitors for diabetes treatment. The findings of this study indicated that ZINC95918625 molecule could be used as a novel STK4 inhibitor in the future studies.

Page 1 from 1     

مجله علمی دانشگاه علوم پزشکی کردستان Scientific Journal of Kurdistan University of Medical Sciences
مجله علمی دانشگاه علوم پزشکی کردستان Scientific Journal of Kurdistan University of Medical Sciences
Persian site map - English site map - Created in 0.05 seconds with 33 queries by YEKTAWEB 4745